Intravenous (IV) Solutions

Intravenous (IV) Solutions

Global Intravenous (IV) Solutions Market to Reach US$21.7 Billion by 2030

The global market for Intravenous (IV) Solutions estimated at US$13.0 Billion in the year 2023, is expected to reach US$21.7 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2023-2030. Parenteral Nutrition, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$15.1 Billion by the end of the analysis period. Growth in the Peripheral Parenteral Nutrition segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 9.1% CAGR

The Intravenous (IV) Solutions market in the U.S. is estimated at US$5.1 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 9.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.4% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Global Intravenous (IV) Solutions Market - Key Trends & Drivers Summarized

Intravenous (IV) solutions are a cornerstone of modern medical treatment, providing a direct method of delivering fluids, medications, and nutrients into the bloodstream. These solutions are crucial for maintaining fluid balance, electrolyte levels, and for delivering drugs and essential nutrients in situations where oral intake is not possible or insufficient. IV solutions are categorized based on their composition and purpose, such as crystalloids, colloids, blood products, and nutrient solutions. Crystalloids, like saline and lactated Ringer`s, are the most commonly used for fluid resuscitation and maintenance. Colloids, including albumin and dextran, are used for volume expansion. Nutrient solutions, which provide carbohydrates, proteins, and fats, are vital for patients requiring parenteral nutrition. The precise composition and administration of these solutions are tailored to meet the specific needs of patients, making them indispensable in various medical settings, from emergency care to chronic disease management.

The growth in the intravenous (IV) solutions market is driven by several factors. The increasing prevalence of chronic diseases such as diabetes, cancer, and gastrointestinal disorders has heightened the demand for IV therapy, which is often essential for managing these conditions. The aging population, with its higher susceptibility to dehydration and nutrient deficiencies, further propels the market, as elderly patients frequently require IV solutions for hydration and nutritional support. Additionally, the rise in surgical procedures and emergency care incidences necessitates a reliable supply of IV solutions for perioperative care and acute treatment. Technological advancements in IV equipment and the development of specialized formulations have expanded the use of IV therapy in various clinical settings. Moreover, the growing focus on home healthcare and outpatient services has increased the demand for portable and easy-to-administer IV solutions, providing patients with greater flexibility and convenience in their treatment regimens. These factors collectively underscore the robust expansion and critical importance of the IV solutions market in the healthcare industry.

Technological advancements and rigorous quality standards have significantly improved the safety and efficacy of IV solutions. Modern IV therapy incorporates advancements such as improved sterility practices, enhanced packaging to prevent contamination, and the development of pre-mixed solutions to minimize preparation errors. Innovations like smart infusion pumps have revolutionized the administration of IV solutions, allowing for precise control over infusion rates and volumes, reducing the risk of over-infusion or under-infusion. Additionally, the integration of electronic health records (EHR) with infusion systems ensures accurate documentation and monitoring of IV therapy, enhancing patient safety. The pharmaceutical industry continues to innovate by developing new formulations and combinations of IV solutions to address complex medical conditions, improving patient outcomes and expanding the therapeutic applications of IV therapy.

Select Competitors (Total 82 Featured) -

• Amanta Healthcare Ltd.
• Anhui Medipharm Co., Ltd.
• AxaParenterals Ltd.
• B. Braun Melsungen AG
• Baxter International Inc.
• Becton, Dickinson and Company
• Fresenius Kabi AG
• Grifols, S.A.
• ICU Medical, Inc.
• JW Life Science
• Otsuka Pharmaceutical Co. Ltd.
• Pfizer Inc.
• Salius Pharma Private Limited.
• Vifor Pharma Management Ltd.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.